Update of the Swiss guidelines on post-treatment Lyme disease syndrome.

Nemeth, Johannes; Bernasconi, Enos; Heininger, Ulrich; Abbas, Mohamed; Nadal, David; Strahm, Carol; Erb, Stefan; Zimmerli, Stefan; Furrer, Hansjakob; Delaloye, Julie; Kuntzer, Thierry; Altpeter, Ekkehard; Sturzenegger, Matthias; Weber, Rainer (2016). Update of the Swiss guidelines on post-treatment Lyme disease syndrome. Swiss medical weekly, 146(w14353), w14353. EMH Schweizerischer Ärzteverlag 10.4414/smw.2016.14353

[img]
Preview
Text
smw.2016.14353.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (620kB) | Preview

Lyme borreliosis is caused by Borrelia burgdorferi sensu lato infection, which responds well to antibiotic therapy in the overwhelming majority of cases. However, despite adequate antibiotic treatment some patients report persisting symptoms which are commonly summarised as post-treatment Lyme disease syndrome (PTLDS). In 2005, the Swiss Society of Infectious Diseases published a case definition for PTLDS. We aimed to review the scientific literature with a special emphasis on the last 10 years, questioning whether the definitions from 2005 are still valid in the light of current knowledge. Furthermore, we describe the clinical history of infection with Borrelia burgdorferi sensu lato, the estimated prevalence of PTLDS, the possible pathogenesis of PTLDS, and treatment options with an emphasis on clinical studies. In summary, we were unable to find a scientific reason for modification of the PTLDS definitions published in 2005. Thus, the diagnostic criteria remain unchanged, namely documented clinical and laboratory evidence of previous infection with B. burgdorferi, a completed course of appropriate antibiotic therapy, symptoms including fatigue, arthralgia, myalgia, cognitive dysfunction or radicular pain persisting for >6 months, a plausible timely association between documented B. burgdorferi infection and onset of symptoms (i.e., persistent or recurrent symptoms that began within 6 months of completion of a recommended antibiotic therapy for early or late Lyme borreliosis), and exclusion of other somatic or psychiatric causes of symptoms. The main therapeutic options remain cognitive behavioural therapy and low-impact aerobic exercise programmes. Growing and unequivocal evidence confirms that prolonged or repeated antibiotic therapy for PTLDS is not beneficial, but potentially harmful and therefore contraindicated. The Guidelines of the Swiss Society of Infectious Diseases offer an evidence based, diagnostic and therapeutic framework for physicians caring for patients suffering from presumptive PTLDS in Switzerland.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Zimmerli, Stefan; Furrer, Hansjakob and Sturzenegger, Matthias

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1424-7860

Publisher:

EMH Schweizerischer Ärzteverlag

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

20 Jan 2017 09:53

Last Modified:

29 Sep 2017 09:32

Publisher DOI:

10.4414/smw.2016.14353

PubMed ID:

27922168

BORIS DOI:

10.7892/boris.91218

URI:

https://boris.unibe.ch/id/eprint/91218

Actions (login required)

Edit item Edit item
Provide Feedback